-
-
-
-
-
-
-
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
-
-
-
-
-
-
-
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
-
-
-
-
-
-
-
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
-
-
-
-
-
-
-
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
-
-
-
-
-
-
-
Standard BioTools (LAB) Announces Multi-Year Strategic Engagement with Bristol Myers Squibb (BMY) for SomaScan Platform in Translational Medicine Research
-
-
-
-
-
-
-
Karuna Therapeutics (KRTX) Discloses Termination of HSR Waiting Period for Bristol-Myers (BMY) Deal
-
-
-
-
-
-
-
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (
-
1,174,431 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

